1. Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947–954.
3. Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001;135:262–268.
4. Hyun JH, Kim JG, Jo SK, Yun IC. A case of toxic hepatitis induced prothionamide (TH-1321) and ethambutol. Korean J Gastroenterol 1970;2:21–27.
5. Kang JK, Park CI, Kim KH, et al. Ketoconazole-induced heaptitis: 4 cases. Korean J Gastroenterol 1986;18:247–252.
6. Jang JS, Seo EG, Han C, et al. Four cases of toxic liver injury associated with Dictamnus dasycarpus. Korean J Hepatol 2008;14:206–212.
7. Kwak SJ, Oh HY, Yeo MA, et al. Fluxetine-induced acute toxic hepatitis. Korean J Hepatol 2000;6:236–240.
8. Kim JB, Sohn JH, Lee HL, et al. Clinical characteristics of acute toxic liver injury. Korean J Hepatol 2004;10:125–134.
9. Seo JC, Jeon WJ, Park SS, et al. Clinical experience of 48 acute toxic hepatitis patients. Korean J Hepatol 2006;12:74–81.
10. Kang SH, Kim JI, Jeong KH, et al. Clinical characteristics of 159 cases of acute toxic hepatitis. Korean J Hepatol 2008;14:483–492.
11. Chun WJ, Yoon BG, Kim NI, et al. A clinical study of patients with acute liver injury caused by herbal medication in Gyeongju area. Korean J Med 2002;63:141–150.
12. Chae HB. Clinical features and diagnosis of drug-induced liver injury. Korean J Hepatol 2004;10(Suppl 1):S7–S18.
13. Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol 2006;44:791–797.
14. Björnsson E, Kalaitzakis E, Av Klinteberg V, Alem N, Olsson R. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther 2007;26:79–85.
15. Bénichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990;11:272–276.
16. Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochrome P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997;26(Suppl 1):S23–S30.
17. De Berardinis V, Moulis C, Maurice M, et al. Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol Pharmacol 2000;58:542–551.
18. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474–485.
19. Dienstag JL. Toxic and drug-induced hepatitis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Internal Medicine. 17th ed. Vol. 2:The McGraw-Hill companies, 2008:1949–1950.
20. Stricker BHCH. Drug-Induced Hepatic Injury. 2nd ed. Amsterdam: Elsevier, 1992.
21. Farrell GC. Drug-Induced Liver Disease. London: Churchill Livingstone, 1994.
22. Pessayre O, Larrey D, Biour M. Drug-induced liver injury. In: Bircher J, Benhanmou JP, McIntyre N, et al, eds. Oxford Textbook of Clinical Hepatology. 2nd ed. Vol. 2. Oxford: Oxford University Press, 1999:1261–1315.
23. Zimmerman HJ. Adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999.
24. Larrey D. Drug-induced liver disease. J Hepatol 2000;32(1 Suppl):S77–S88.
26. Kleiner DE. The pathology of drug-induced liver disease. Semin Liver Dis 2009;29:364–372.